Multi-omics Analysis of Core E3 Ubiquitin Ligase Identifies Prognostic Biomarkers Associated with Immune Infiltration and Drug Sensitivity in Lung Adenocarcinoma

Overview

Journal J Cancer

Date 2025 Feb 3

PMID 39895786

Authors

Yuan-Xiang Shi

Jia Wang

Zhen-Lin Jiang

Jian-Hua Yan

Affiliations

Soon will be listed here.

Abstract

Ubiquitination is involved in several tumor immunomodulatory processes, and targeting E3 ubiquitin ligases has substantial potential in cancer therapy. In this study, the key E3 ubiquitin ligases involved in regulating the malignant progression of LUAD were studied. We first systematically investigated the expression landscape, prognosis, immune infiltration, drug sensitivity, and potential molecular mechanisms of these hub genes in LUAD. was localized by immunofluorescence analysis in tumor cell lines, and its expression level was determined by immunohistochemistry on tissue chips. Single-cell analysis and spatial transcriptomics were used to determine expression in multiple cell types. Molecular docking was performed via computer simulation to verify the ability of drugs to bind to target genes. We found that these hub genes are specifically overexpressed in LUAD and are associated with poor patient prognosis. All five E3 ubiquitin ligase genes were negatively correlated with B cells and dendritic cells but positively related to neutrophil immune infiltration. In addition, analysis of the CTRP and GDSC databases revealed that the sensitivity to multiple antitumor drugs increased when was highly expressed. GSEA enrichment analysis demonstrated that the G2M_CHECKPOINT, MTORC1_SIGNALING, OXIDATIVE_PHOSPHORYLATION, and GLYCOLYSIS signaling pathways were enriched when was highly expressed. Further correlation analysis indicated that was positively correlated with the expression of the key genes mTOR, S6K1, and 4E-BP1 and the autophagy-related gene ULK1 in the mTORC1 signaling pathway. These key E3 ubiquitin ligases serve as potential molecular biomarkers for predicting the prognosis, immune response, and drug sensitivity of LUAD patients.

References

Ji J, Ding K, Luo T, Zhang X, Chen A, Zhang D . TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα. Cell Death Differ. 2020; 28(1):367-381. PMC: 7853150. DOI: 10.1038/s41418-020-00606-w. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Liu Y, Tao S, Liao L, Li Y, Li H, Li Z . TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway. Nat Commun. 2020; 11(1):348. PMC: 6969153. DOI: 10.1038/s41467-019-14190-2. View

Deng L, Chen L, Zhao L, Xu Y, Peng X, Wang X . Ubiquitination of Rheb governs growth factor-induced mTORC1 activation. Cell Res. 2018; 29(2):136-150. PMC: 6355928. DOI: 10.1038/s41422-018-0120-9. View

Toma-Fukai S, Shimizu T . Structural Diversity of Ubiquitin E3 Ligase. Molecules. 2021; 26(21). PMC: 8586995. DOI: 10.3390/molecules26216682. View

Faubert B, Solmonson A, DeBerardinis R . Metabolic reprogramming and cancer progression. Science. 2020; 368(6487). PMC: 7227780. DOI: 10.1126/science.aaw5473. View

Siegel R, Giaquinto A, Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):12-49. DOI: 10.3322/caac.21820. View

Shi Y, Yan J, Liu W, Deng J . Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity. BMC Cancer. 2023; 23(1):408. PMC: 10163697. DOI: 10.1186/s12885-023-10895-2. View

Gao T, Liu Z, Wang Y, Cheng H, Yang Q, Guo A . UUCD: a family-based database of ubiquitin and ubiquitin-like conjugation. Nucleic Acids Res. 2012; 41(Database issue):D445-51. PMC: 3531133. DOI: 10.1093/nar/gks1103. View

10.

Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G . A pathology atlas of the human cancer transcriptome. Science. 2017; 357(6352). DOI: 10.1126/science.aan2507. View

11.

Li S, Liu Y, Yuan L, Ji M, Zhang A, Li H . Autocrine INSL5 promotes tumor progression and glycolysis via activation of STAT5 signaling. EMBO Mol Med. 2020; 12(9):e12050. PMC: 7507000. DOI: 10.15252/emmm.202012050. View

12.

Pickart C, Eddins M . Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta. 2004; 1695(1-3):55-72. DOI: 10.1016/j.bbamcr.2004.09.019. View

13.

Shi Y, Zhang W, Dai P, Deng J, Tan L . Comprehensive analysis of KCTD family genes associated with hypoxic microenvironment and immune infiltration in lung adenocarcinoma. Sci Rep. 2022; 12(1):9938. PMC: 9200823. DOI: 10.1038/s41598-022-14250-6. View

14.

He W, Meng J . CDC20: a novel therapeutic target in cancer. Am J Transl Res. 2023; 15(2):678-693. PMC: 10006751. View

15.

Sampson C, Wang Q, Otkur W, Zhao H, Lu Y, Liu X . The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin Transl Med. 2023; 13(3):e1204. PMC: 9991012. DOI: 10.1002/ctm2.1204. View

16.

Yang H, Rudge D, Koos J, Vaidialingam B, Yang H, Pavletich N . mTOR kinase structure, mechanism and regulation. Nature. 2013; 497(7448):217-23. PMC: 4512754. DOI: 10.1038/nature12122. View

17.

Dagar G, Kumar R, Yadav K, Singh M, Pandita T . Ubiquitination and deubiquitination: Implications on cancer therapy. Biochim Biophys Acta Gene Regul Mech. 2023; 1866(4):194979. DOI: 10.1016/j.bbagrm.2023.194979. View

18.

Bui Q, Hong J, Kwak M, Lee J, Lee P . Ubiquitin-Conjugating Enzymes in Cancer. Cells. 2021; 10(6). PMC: 8227520. DOI: 10.3390/cells10061383. View

19.

Mizuno H, Kitada K, Nakai K, Sarai A . PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009; 2:18. PMC: 2689870. DOI: 10.1186/1755-8794-2-18. View

20.

Shi Y . Identification of the molecular function of tripartite motif containing 58 in human lung cancer. Oncol Lett. 2021; 22(3):685. PMC: 8335731. DOI: 10.3892/ol.2021.12946. View